A Novel Prognostic Model Based on Ferroptosis-Related Gene Signature for Bladder Cancer

BackgroundBladder cancer (BC) is a molecular heterogeneous malignant tumor; the treatment strategies for advanced-stage patients were limited. Therefore, it is vital for improving the clinical outcome of BC patients to identify key biomarkers affecting prognosis. Ferroptosis is a newly discovered pr...

Full description

Bibliographic Details
Main Authors: Libo Yang, Chunyan Li, Yang Qin, Guoying Zhang, Bin Zhao, Ziyuan Wang, Youguang Huang, Yong Yang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.686044/full
id doaj-a3d693170c0c4f518b4d031c04b43177
record_format Article
spelling doaj-a3d693170c0c4f518b4d031c04b431772021-08-06T08:32:07ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-08-011110.3389/fonc.2021.686044686044A Novel Prognostic Model Based on Ferroptosis-Related Gene Signature for Bladder CancerLibo Yang0Chunyan Li1Yang Qin2Guoying Zhang3Bin Zhao4Ziyuan Wang5Youguang Huang6Yong Yang7Department of Urology, The Third Affiliated Hospital of Kunming Medical University, Kunming, ChinaSecond Department of Head and Neck Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, ChinaDepartment of Urology, The Third Affiliated Hospital of Kunming Medical University, Kunming, ChinaDepartment of Urology, The Third Affiliated Hospital of Kunming Medical University, Kunming, ChinaDepartment of Urology, The Third Affiliated Hospital of Kunming Medical University, Kunming, ChinaDepartment of Yunnan Tumor Research Institute, The Third Affiliated Hospital of Kunming Medical University, Kunming, ChinaDepartment of Yunnan Tumor Research Institute, The Third Affiliated Hospital of Kunming Medical University, Kunming, ChinaDepartment of Urology, The Third Affiliated Hospital of Kunming Medical University, Kunming, ChinaBackgroundBladder cancer (BC) is a molecular heterogeneous malignant tumor; the treatment strategies for advanced-stage patients were limited. Therefore, it is vital for improving the clinical outcome of BC patients to identify key biomarkers affecting prognosis. Ferroptosis is a newly discovered programmed cell death and plays a crucial role in the occurrence and progression of tumors. Ferroptosis-related genes (FRGs) can be promising candidate biomarkers in BC. The objective of our study was to construct a prognostic model to improve the prognosis prediction of BC.MethodsThe mRNA expression profiles and corresponding clinical data of bladder urothelial carcinoma (BLCA) patients were downloaded from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. FRGs were identified by downloading data from FerrDb. Differential analysis was performed to identify differentially expressed genes (DEGs) related to ferroptosis. Univariate and multivariate Cox regression analyses were conducted to establish a prognostic model in the TCGA cohort. BLCA patients from the GEO cohort were used for validation. Gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and single-sample gene set enrichment analysis (ssGSEA) were used to explore underlying mechanisms.ResultsNine genes (ALB, BID, FADS2, FANCD2, IFNG, MIOX, PLIN4, SCD, and SLC2A3) were identified to construct a prognostic model. Patients were classified into high-risk and low-risk groups according to the signature-based risk score. Receiver operating characteristic (ROC) and Kaplan–Meier (K–M) survival analysis confirmed the superior predictive performance of the novel survival model based on the nine-FRG signature. Multivariate Cox regression analyses showed that risk score was an independent risk factor associated with overall survival (OS). GO and KEGG enrichment analysis indicated that apart from ferroptosis-related pathways, immune-related pathways were significantly enriched. ssGSEA analysis indicated that the immune status was different between the two risk groups.ConclusionThe results of our study indicated that a novel prognostic model based on the nine-FRG signature can be used for prognostic prediction in BC patients. FRGs are potential prognostic biomarkers and therapeutic targets.https://www.frontiersin.org/articles/10.3389/fonc.2021.686044/fullferroptosisprognosisbiomarkersbladder cancerbladder urothelial carcinoma
collection DOAJ
language English
format Article
sources DOAJ
author Libo Yang
Chunyan Li
Yang Qin
Guoying Zhang
Bin Zhao
Ziyuan Wang
Youguang Huang
Yong Yang
spellingShingle Libo Yang
Chunyan Li
Yang Qin
Guoying Zhang
Bin Zhao
Ziyuan Wang
Youguang Huang
Yong Yang
A Novel Prognostic Model Based on Ferroptosis-Related Gene Signature for Bladder Cancer
Frontiers in Oncology
ferroptosis
prognosis
biomarkers
bladder cancer
bladder urothelial carcinoma
author_facet Libo Yang
Chunyan Li
Yang Qin
Guoying Zhang
Bin Zhao
Ziyuan Wang
Youguang Huang
Yong Yang
author_sort Libo Yang
title A Novel Prognostic Model Based on Ferroptosis-Related Gene Signature for Bladder Cancer
title_short A Novel Prognostic Model Based on Ferroptosis-Related Gene Signature for Bladder Cancer
title_full A Novel Prognostic Model Based on Ferroptosis-Related Gene Signature for Bladder Cancer
title_fullStr A Novel Prognostic Model Based on Ferroptosis-Related Gene Signature for Bladder Cancer
title_full_unstemmed A Novel Prognostic Model Based on Ferroptosis-Related Gene Signature for Bladder Cancer
title_sort novel prognostic model based on ferroptosis-related gene signature for bladder cancer
publisher Frontiers Media S.A.
series Frontiers in Oncology
issn 2234-943X
publishDate 2021-08-01
description BackgroundBladder cancer (BC) is a molecular heterogeneous malignant tumor; the treatment strategies for advanced-stage patients were limited. Therefore, it is vital for improving the clinical outcome of BC patients to identify key biomarkers affecting prognosis. Ferroptosis is a newly discovered programmed cell death and plays a crucial role in the occurrence and progression of tumors. Ferroptosis-related genes (FRGs) can be promising candidate biomarkers in BC. The objective of our study was to construct a prognostic model to improve the prognosis prediction of BC.MethodsThe mRNA expression profiles and corresponding clinical data of bladder urothelial carcinoma (BLCA) patients were downloaded from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. FRGs were identified by downloading data from FerrDb. Differential analysis was performed to identify differentially expressed genes (DEGs) related to ferroptosis. Univariate and multivariate Cox regression analyses were conducted to establish a prognostic model in the TCGA cohort. BLCA patients from the GEO cohort were used for validation. Gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and single-sample gene set enrichment analysis (ssGSEA) were used to explore underlying mechanisms.ResultsNine genes (ALB, BID, FADS2, FANCD2, IFNG, MIOX, PLIN4, SCD, and SLC2A3) were identified to construct a prognostic model. Patients were classified into high-risk and low-risk groups according to the signature-based risk score. Receiver operating characteristic (ROC) and Kaplan–Meier (K–M) survival analysis confirmed the superior predictive performance of the novel survival model based on the nine-FRG signature. Multivariate Cox regression analyses showed that risk score was an independent risk factor associated with overall survival (OS). GO and KEGG enrichment analysis indicated that apart from ferroptosis-related pathways, immune-related pathways were significantly enriched. ssGSEA analysis indicated that the immune status was different between the two risk groups.ConclusionThe results of our study indicated that a novel prognostic model based on the nine-FRG signature can be used for prognostic prediction in BC patients. FRGs are potential prognostic biomarkers and therapeutic targets.
topic ferroptosis
prognosis
biomarkers
bladder cancer
bladder urothelial carcinoma
url https://www.frontiersin.org/articles/10.3389/fonc.2021.686044/full
work_keys_str_mv AT liboyang anovelprognosticmodelbasedonferroptosisrelatedgenesignatureforbladdercancer
AT chunyanli anovelprognosticmodelbasedonferroptosisrelatedgenesignatureforbladdercancer
AT yangqin anovelprognosticmodelbasedonferroptosisrelatedgenesignatureforbladdercancer
AT guoyingzhang anovelprognosticmodelbasedonferroptosisrelatedgenesignatureforbladdercancer
AT binzhao anovelprognosticmodelbasedonferroptosisrelatedgenesignatureforbladdercancer
AT ziyuanwang anovelprognosticmodelbasedonferroptosisrelatedgenesignatureforbladdercancer
AT youguanghuang anovelprognosticmodelbasedonferroptosisrelatedgenesignatureforbladdercancer
AT yongyang anovelprognosticmodelbasedonferroptosisrelatedgenesignatureforbladdercancer
AT liboyang novelprognosticmodelbasedonferroptosisrelatedgenesignatureforbladdercancer
AT chunyanli novelprognosticmodelbasedonferroptosisrelatedgenesignatureforbladdercancer
AT yangqin novelprognosticmodelbasedonferroptosisrelatedgenesignatureforbladdercancer
AT guoyingzhang novelprognosticmodelbasedonferroptosisrelatedgenesignatureforbladdercancer
AT binzhao novelprognosticmodelbasedonferroptosisrelatedgenesignatureforbladdercancer
AT ziyuanwang novelprognosticmodelbasedonferroptosisrelatedgenesignatureforbladdercancer
AT youguanghuang novelprognosticmodelbasedonferroptosisrelatedgenesignatureforbladdercancer
AT yongyang novelprognosticmodelbasedonferroptosisrelatedgenesignatureforbladdercancer
_version_ 1721219264633896960